NNC6019-0001

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Heart FailureTransthyretin Amyloid Cardiomyopathy (ATTR-CM)

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

1

NNC6019-0001

Novo Nordisk

Phase 3

12

Bayer Aspirin

Bayer

Preclinical

23

Brethine

Sanofi

Preclinical

14

Medrol

Pfizer

Preclinical

15

Amidate

Pfizer

Preclinical

16

Zemplar

AbbVie

Preclinical

—7

Adriamycin

Pfizer

Preclinical

—8

Savaysa

Daiichi Sankyo

Preclinical

—9

Activase

Roche

Preclinical

—10

Xifaxan

SSalix

Preclinical

2Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Heart Failure1 trial

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Active, not recruiting·Novo Nordisk·Phase 2·NCT06260709·80 enrolled

Heart Disease1 trial

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Completed·Novo Nordisk·Phase 2·NCT05442047·105 enrolled

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)1 trial

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Recruiting·Novo Nordisk·Phase 3·NCT07207811·1,280 enrolled

Details

Drug Info

Related News